

Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.

705 North Goliad, Suite A

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

Cancer Communication: Navigating the Highways

Selected References

Attacking the signal at the switch: Unraveling the mysteries of mTOR inhibition in multiple tumor types. (2008). Virginia: Postgraduate Institute for Medicine and Clinical Care Options, Inc. (monograph)

Banchereau, J. & Palucka, K. (2005). Dendritic cells as therapeutic vaccines against cancer. *Nature Reviews Immunology*, 5, 296-306.

Buchsel, P. & DeMeyer, E. (2006). Dendritic cells: Emerging roles in tumor immunotherapy. *Clinical Journal of Oncology Nursing*, 10(5), 198-205.

Colony Stimulating Factors: Beyond Neutrophil Recovery. (2001). Pittsburgh: *Oncology Education Services*. (online monograph)
<http://www.ons.org/ceCentral/pdf/colonyMono.pdf>

Cytokines & B-Cell Malignancies: Maximizing Therapeutic Outcomes. (2006). Pittsburgh: *Oncology Education Services*. (online monograph)
http://www.ons.org/ceCentral/pdf/b_Cell_monograph.pdf


Dreicer, R., See, W., & Klein, E. (2001). Phase II trial of GM-CSF in advanced prostate cancer. *Investigation of New Drugs*, 19, 261-265.

Dendritic Cells: The Sentry Cells of the Hematopoietic Cell Line. (2004). Pittsburgh: *Oncology Education Services*. (online monograph)
<http://www.ons.org/ceCentral/pdf/dendriticMono.pdf>

Eaby, B., Culkin, A., & Lacouture, M. (2008). An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. *Clinical Journal of Oncology Nursing*, 12(2), 283-290.

Esper, P., Gale, D., & Muehlbauer, P. (2007). What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. *Clinical Journal of Oncology Nursing*, 11(5), 659-666.

Herbst, R., Fox, L., Viele, C. & Messner, C. (2006). Managing rash and other skin reactions to targeted treatments. New York: Elsevier Oncology.



Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.

705 North Goliad, Suite A

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

Gowland, P., Vlamakis, J., Koch, J., Lloyd, K., Spaulding, J.B. Evaluation of *Regenecare* topical gel for treatment of adverse rash symptoms associated with EGFR inhibitor drugs. Program and abstracts of the 33rd Annual Congress of the Oncology Nursing Society; May 15-18, 2008; Philadelphia, Pennsylvania. Abstract 2980.

Honkoop, A., Bakker, L., Hoekman, K., Meyer, S., Meyer, O., van Groeningen, C., Van Diest, P., Boven, E., Van Der Wall, E., Giaccone, G., Wagstaff, J., & Pinedo, H. (1999). Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. *The Oncologist*, 4, 106-111.

Janeway, C., Murphy, K., Travers, P. & Walport, M. (2007). *Immunobiology: The Immune System* (7th ed). New York: Garland Publishing.

Leong, S. P., Enders-Zohr, P., Zhou, Y. M., Stuntebeck, S., Habib, F. A., & Allen, R. E., Jr. (1999). Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. *Journal of Immunotherapy*, 22, 166-174.


Lynch, T., Kim, S., Eaby, B., Garey, J., West, D. & Lacoutoure, M. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. *The Oncologist*, 12(5), 610-621.

O'Day, S., Boasberg, P., Piro, L., Kristedja, T., Wang, H., Martin, M., Deck, R., Ames, P., Shinn, K., Kim, H., Fournier, P., Gammon, G. (2002). Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent bio-chemotherapy. *Clinical Cancer Research*, 8, 2775-2781.

Oishi, K. (2008). Clinical approaches to minimize rash associated with EGFR inhibitors. *Oncology Nursing Forum*, 35, 103-111.

Pinedo H., & Bulter, J. (2000). The hidden treasures of the primary tumor: extended neoadjuvant chemotherapy plus GM-CSF in locally advanced cancer. *Proceeding of the 11th National Cancer Institute, Eastern Oncology T. C., AACR Symposium*, 44-48.

Pinedo, H. M., Buter, J., Luykx-de-Bakker, S. A., van Hensbergen, Y., Heideman, D. A. Van Diest, P. J. et al. (2003). Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: Effect on tumour-draining lymph node dendritic cells. *European Journal of Cancer*, 39, 1061-1067.



Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.

705 North Goliad, Suite A

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

- Rosenbaum, S., Wu, S., Newman, M., West, D., Kuzel, T. & Lacouture, M. (2008). Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. *Supportive Care in Cancer*, 16, 557-566.
- Skin Reactions and cancer therapy: guidelines for identifying and managing skin-related side effects during your therapy. (2006). Connecticut: Bayer Pharmaceuticals Corporation. (brochure)
- Small, E. J., Reese, D. M., Um, B., Whisenant S., Dixon, S. C., & Figg, W. D. (1999). Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. *Clinical Cancer Research*, 5, 1738-1744.
- Spitler, L., Grossbard, M., Ernstaff, M., Silver, G., Jacobs, M., Hayes, F., & Soong, S. (2000). Adjuvant therapy of stage II and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. *Journal of Clinical Oncology*, 18(8), 1614-1621.
- Spitler, L. E. (2002). Adjuvant therapy of melanoma. *Oncology*, 16(1) (supplement 1), 40-48.
- Steinman, R. (2007). Dendritic cells: versatile controllers of the immune system. *Nature Medicine*, 11(10), vii – xi.
- Steinman, R. & Banchereau, J. (2007). Taking dendritic cells into medicine. *Nature*, 449, 419-426.
- Sompayrac, L. (2008). *How the Immune System Works* (3rd ed). Massachusetts: Blackwell Publishing.
- Viale, P. & Yamamoto, D. (2008). Cardiovascular toxicity associated with cancer treatment. *Clinical Journal of Oncology Nursing*, 12(4), 627-638.
- Wood, L. & Manchen, B. (2007). Sorafenib: A promising new targeted therapy for renal cell carcinoma. *Clinical Journal of Oncology Nursing*, 11(5), 649-656.
- Wilkes, G. (2008). Managing drug infusion reactions: Focus on cetuximab monoclonal antibody therapy. *Clinical Journal of Oncology Nursing*, 12(3), 530-532.

The material in this program was compiled by Creative Cancer Concepts, Inc. with an educational grant from Bayer HealthCare Pharmaceuticals, Inc. This information should not be used by clinicians in the management of patients without evaluation of the patients' condition, possible contraindications, review of the manufacturer's product information, and consultation with recommendations of other authorities.

©2008 Creative Cancer Concepts, Inc. All rights reserved.